CD274 and cancer: The significant pH-dependent increment of BEI may represent an opportunity of benzamidoxime derivatives to achieve a specific targeting of cancer cells expressing PD-L1 in the acidic tumor microenvironment, thus reducing the risk of iRAEs associated to a wider targeting against other cells expressing PD-L1.